Dihexa
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic oligopeptide derived from angiotensin IV, engineered to potently activate the HGF/c-Met signaling pathway, which plays a central role in synaptogenesis and dendritic spine formation in the brain. In rodent models of Alzheimer's disease and cognitive impairment it produces striking improvements in learning and spatial memory at very low doses, with an estimated in vitro potency approximately 10 million times greater than BDNF for inducing synaptogenesis. No human clinical trials have been conducted; Dihexa exists entirely in preclinical research stages with no published pharmacokinetic, safety, or dose-finding data in humans. Given its potent receptor activity and completely unknown human risk and benefit profile, it is among the most speculative compounds in the research peptide space.
Evidence last reviewed: 19 Apr 2026
Not a routine supplement — not recommended for self-directed use.
Information here is educational only, not a recommendation to use. See our Safety page.
Verify this peptide on CertiPep
certipep.ch — anonymous purity & characterization service
Evidence is from research or clinical settings — does not imply safety outside supervised contexts.
The evidence for Dihexa is primarily based on animal models, showing potential cognitive benefits and synaptogenesis promotion. However, there are significant gaps in human data, including safety and pharmacokinetics.
Cognitive enhancementAnimal models · Systematic reviewVery low
The systematic review suggests potential cognitive benefits of angiotensin IV and related compounds in animal models.
SynaptogenesisAnimal models · TheoreticalVery low
Dihexa is theorized to promote synaptogenesis through potentiation of HGF/Met signaling.
Combining Dihexa with Huperzine A can enhance cognitive performance and support neuroplasticity. Dihexa is known for its neuroprotective and cognitive-enhancing properties, while Huperzine A supports memory and focus.